

# Adjudication of Adverse Events Using AI

Saman Parvaneh, PhD

Director, Data Science and AI, Edwards Lifesciences

November 15, 2023



Edwards

**Edwards Lifesciences 2020-Present**

Structured and unstructured data

*Present*

2020

2015

**Postdoc 2012-2014**Wearable Sensors (Frailty  
and Outcome Prediction)

2010

**Philips Research 2015-2020**

Electronic Health Record and Biosignals

**Ph.D. 2005-2011**

ECG (Atrial Fibrillation Prediction)

**M.Sc. 2003-2005**Medical Imaging (MRI)  
and Speech (Infant Cry)

2005

**B.Sc. 1998-2003**

Bioinstrumentation

2000

# Disclaimer

The views expressed in this presentation are my own and do not reflect the views of my employer. I am presenting my personal opinions and analysis, and any errors or omissions are solely my responsibility.

# Outline



**Endpoint Adjudication  
and Clinical Event  
Committee (CEC)**



**Artificial Intelligence  
for endpoint  
adjudication (eCEC)**





**Results and  
lesson learned**

# Endpoint Adjudication & CEC

- Endpoint adjudication in clinical trials is a process to ensure that consistent criteria were applied throughout the trial in the assessment of study endpoints.
- Often, clinical outcomes are adjudicated by Clinical Event Committees (CEC) to ensure data quality and patient safety.
- Clinical Event Committee (CEC) is a group of medical experts that review pre-determined adverse events throughout a trial.
- The CEC provides an independent, unbiased, and objective adjudication of the protocol-specified events for a trial.

# Adjudication by CEC



# CEC Adjudication and FDA

## Guidance for Clinical Trial Sponsors

### Establishment and Operation of Clinical Trial Data Monitoring Committees

Sponsors may also choose to establish an endpoint assessment/adjudication committee (these may also be known as clinical events committees) in certain trials to review important endpoints reported by trial investigators to determine whether the endpoints meet protocol-specified criteria [1].

For questions on the content of this guidance, contact the Office of Communication, Training, and Manufacturers Assistance (CBER) at 800-835-4709 or 301-827-1800.

U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Biologics Evaluation and Research (CBER)  
Center for Drug Evaluation and Research (CDER)  
Center for Devices and Radiological Health (CDRH)  
March 2006

OMB Control No. 0910-0581  
Current expiration date available at <https://www.reginfo.gov>  
See additional PRA statement in Section 8 of this guidance

[1] Guidance for Clinical Trial Sponsors  
Establishment and Operation of Clinical Trial Data Monitoring Committees -  
<https://www.fda.gov/media/75398/download>

# Automation of Endpoint Adjudication

- Automation of endpoint adjudication represents an opportunity to enhance adjudication consistency, improve turnaround time, and reduce costs when CEC adjudication is no longer performed.
- The availability of clinical data adjudicated by CEC allows the use of Artificial Intelligence (AI) for endpoint adjudication.



# Artificial Intelligence and Machine Learning



**Mat Velloso**

@matvelloso



Difference between machine learning and AI:

If it is written in Python, it's probably machine learning

If it is written in PowerPoint, it's probably AI

5:25 PM · Nov 22, 2018



188



8.7K




22K



375




# AI-based Adverse Events Adjudication



CEC vs. AI-based Adjudication (EW: Edwards Lifesciences, AE: Adverse Event)



# Rehospitalization Adjudication using AI




Variable Group	Number of Variables	Examples
Numeric	1	Number of days from procedure to event
Categorical	2	MedDRA System Organ Classes (SOC) and MedDRA Preferred Term (PT)

# MedDRA Coding

- MedDRA stands for Medical Dictionary for Regulatory Activities.
- It is a standardized medical terminology to facilitate the sharing of regulatory information internationally for medical products used by humans.
- MedDRA is used for registration, documentation and safety monitoring of medical products before and after being authorized for sale.



# Rehospitalization Adjudication using AI





	Non-CV Rehospitalization	CV Rehospitalization
Training/validation	442 (59.73%)	298 (40.27%)
Test	110 (59.46)	75 (40.54)
Unseen test	29 (59.18)	20 (40.82)

# Rehospitalization Adjudication using AI

- One-hot encoding was used for categorical variables.
- Seventeen different AI algorithms were tested.
- Data is imbalanced. Therefore, AI model with the highest F1 score (Catboost Classifier) was selected for further improvement.
- Catboost is an advanced boosting algorithm.
- To find feature importance and provide interpretability for AI-based adjudication, SHAP (SHapley Additive explanation) method is employed.

# Rehospitalization Adjudication using AI



Non-Cardiovascular

Cardiovascular

True Class

26

3

False Positive

3  
False Negative

17

Non-Cardiovascular

Cardiovascular

Predicted Class

Non-Cardiovascular

Cardiovascular

True Class

95

15

False Positive

25  
False Negative

50


Non-Cardiovascular

Cardiovascular

Predicted Class

# Interpreting Model

Feature Importance





# Example Case (1)

## CV/Non-CV Rehospitalization

**Site:** CV Rehosp

**CEC:** CV Rehosp



**eCEC:** CV Rehosp

(Confidence Score: 98.3%)

AETERM\_SOC = Cardiac disorders

PRC2EVENT\_DAYS = 993.0

AETERM\_PT = others\_infrequent



## Example Case (2)

### CV/Non-CV Rehospitalization

**Site:** Non-CV Rehosp


**CEC:** Non-CV Rehosp

**eCEC:** Non-CV Rehosp  
(Confidence Score: 99.5%)


AETERM\_SOC = Infections and infestations

PRC2EVENT\_DAYS = 1133.0

AETERM\_PT = Cellulitis




# Benefits of Using Interpretable Approach



Building Trust




Better Adoption



Feedback for Improvement

# Human-In-The-Loop

- It is a design paradigm that involves integrating humans into the decision-making process of artificial intelligence (AI) systems.
- The term "human-in-the-loop" refers to the idea that **AI systems** should be designed to **work with human operators** rather than replace them entirely.




# Human-In-The-Loop and AI-based Adjudication

The screenshot displays a web browser window with two tabs labeled 'THV eCEC Dashboard'. The address bar shows the URL 'thvclinicalai.edwards.com/ecec/p3/'. The main content area is titled 'Safety Officer' and contains the following elements:

- A label 'QC Reviewed by Safety Officer:' followed by a dropdown menu currently set to 'Not Accepted'.
- A red rectangular alert box with the text 'If Not Accepted, Please Provide Reason!'.
- A red text label 'If Not Accepted, Reason (Mandatory):' above a large, empty text input field.
- A label 'Select Query Type:' above a dropdown menu.
- The 'Select Query Type' dropdown menu is open, showing a list of options: 'CEC Query', 'No Action', 'CEC Query' (highlighted in blue), 'Site Query', 'eCEC Query', and 'Medra Coding Query'.


# Integration of AI-based adjudication into workflow over time

- Out of 91 cases with a mismatch between CEC and AI-based algorithm:
  - 17 cases require re-review by CEC
  - 6 cases required a MedDRA coding update
- Results suggest the potential for using AI-based adjudication for QC when CEC adjudication is required.



# Is AI **replacing** CEC?





AI could be **helpful in  
resource-limited setting**



**Human-in-the-loop is  
the key** for a successful  
AI for healthcare



# Key Takeaways

- Working with a multidisciplinary team is the key to success.
- Endpoint adjudication using AI techniques is possible.
- By increasing data size, further improvement of the AI algorithm is possible.
- AI-based adjudication can reduce the cost and increase efficiency to get consistent endpoint adjudication in place of CEC adjudication where CEC adjudication is not required or feasible.
- AI confidence score and/or disagreement between eCEC and other human judgments could be used for prioritizing QC.
- The robustness of AI-based adjudication across different trials needs to be explored, as endpoint definitions may change from trial to trial.
- Collaboration across different companies and FDA provide an opportunity to have more accurate and robust AI-based adjudication

# Team



Zaniar Ardalan

Sr Data Scientist  
Data Science & AI



Matt Song

Sr Data Engineer  
Data Science & AI



Ihsan Hasan

Director  
Medical Safety



Elena Khury

Sr Analyst  
Clinical Safety Systems



Carlie Gaunt

Director  
Medical Safety



Michael Lu

Director  
Biostatistics



Wei Liu

VP  
Biostatistics



Terri Johnson

Sr Director  
Biostatistics

# Thank you



saman\_parvaneh@edwards.com

Edwards, Edwards Lifesciences, and the stylized E logo are trademarks or service marks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

© 2023 Edwards Lifesciences Corporation. All rights reserved.

**Edwards Lifesciences** • One Edwards Way, Irvine CA 92614 USA • [edwards.com](https://www.edwards.com)




Edwards

# AI is a broad term




## Artificial intelligence (AI)

Any technique that enables a machine to mimic human intelligence



## Machine learning (ML)

Mathematical and statistical methods that enable machines to learn tasks from data without explicitly programming



## Deep learning

Neural networks with many layers that learn representations and patterns directly from data

# Our goal is to create AI that is

**Simple**

**Reliable**


**Generalizable**

**Interpretable**

**Fair**




# The myth of big data in medicine



“This promise turns out to be a myth. The more and more data you have, the less you are able to curate the quality of that data.” Professor G. Clifford

# Statistical Approach for initial data screening

## ■ Univariable Analysis



- Correlation/Collinearity among covariates
  - Some echo parameters have high collinearity.
  - Variables with  $>0.8$  absolute correlation will be eliminated
  - Keep the one variable with higher absolute effect size if highly collinear among multiple variables.
- After removing columns with much missing and high collinearity, we kept 107 variables into AI modeling.

# Results Summary

Measure	Test	Unseen Test	Derivations
<b>Sensitivity</b>	0.6667	0.8500	$TPR = TP / (TP + FN)$
<b>Specificity</b>	0.8636	0.8966	$SPC = TN / (FP + TN)$
<b>Precision</b>	0.7692	0.8500	$PPV = TP / (TP + FP)$
<b>Negative Predictive Value</b>	0.7917	0.8966	$NPV = TN / (TN + FN)$
<b>False Positive Rate</b>	0.1364	0.1034	$FPR = FP / (FP + TN)$
<b>False Discovery Rate</b>	0.2308	0.1500	$FDR = FP / (FP + TP)$
<b>False Negative Rate</b>	0.3333	0.1500	$FNR = FN / (FN + TP)$
<b>Accuracy</b>	0.7838	0.8776	$ACC = (TP + TN) / (P + N)$
<b>F1 Score</b>	0.7143	0.8500	$F1 = 2TP / (2TP + FP + FN)$




# Rehospitalization Adjudication using AI/ML





Variable Group	Number of Variables	Examples
Demographics	4	RACE, AGE, SEX, BMI
Risk Scores	8	STSRSCR, FRIDX07, GRASPAVG, ALBUM
Baseline Measures	39	HEARTRATE, RHYTHM, LVEDD, LVEF, AOVMG, NYHA
Echocardiography	53	HEARTRATE, RHYTHM, LVEDD, LVEF, AOVMG, NYHA
Text/Categories	3	AE TERM, AE MEDDRA PREFERED TERM (PT), AE DESCRIPTION

# Results

- Removed 5 subjects where time between event and adjudication was negative
- Handled missing values
- Handled correlated variables



# Performance on Test Data



## QC



6 out of 74 cases in ML Problem groups had coding problem.

